Cemdisiran
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atypical Hemolytic Uremic Syndrome
Conditions
Atypical Hemolytic Uremic Syndrome
Trial Timeline
Sep 19, 2017 → Sep 12, 2018
NCT ID
NCT03303313About Cemdisiran
Cemdisiran is a phase 2 stage product being developed by Alnylam Pharmaceuticals for Atypical Hemolytic Uremic Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03303313. Target conditions include Atypical Hemolytic Uremic Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03303313 | Phase 2 | Withdrawn |
Competing Products
18 competing products in Atypical Hemolytic Uremic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Ropeginterferon Alfa-2B | PharmaEssentia | Phase 2 | 51 |
| CCX168 | Amgen | Phase 2 | 51 |
| Tazemetostat + Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 49 |
| Axatilimab + Azacitidine | Incyte | Phase 1/2 | 38 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 44 |
| Apatinib Mesylate | Brain Biotech | Pre-clinical | 15 |
| azurin-derived cell-penetrating peptide p28 | Brain Biotech | Phase 1 | 25 |